|
Volume 270,
Number 50,
Issue of December 15, 1995 pp. 29760-29765
©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Lysolecithin-induced
Alteration of Subendothelial Heparan Sulfate Proteoglycans Increases
Monocyte Binding to Matrix
(Received for publication, August 29, 1995; and in revised form, October 2,
1995)
Pillarisetti
Sivaram ,
Joseph C.
Obunike,
Ira
J.
Goldberg
The cause and consequence of altered proteoglycans in
atherosclerosis are poorly understood. To determine whether
proteoglycans affect monocyte binding, we studied the effects of
heparin and proteoglycan degrading enzymes on THP-1 monocyte adhesion
to subendothelial matrix (SEM). Monocyte binding increased about 2-fold
after SEM was treated with heparinase. In addition, heparin decreased
monocyte binding to fibronectin, a known SEM protein, by 60%. These
data suggest that SEM heparan sulfate inhibits monocyte binding to SEM
proteins. We next examined whether lysolecithin, a constituent of
modified lipoproteins, affects endothelial heparan sulfate proteoglycan
(HSPG) production and monocyte binding. Lysolecithin (10-200
µM) decreased total SO in SEM
(20-75%). 2-fold more monocytes bound to SEM from lysolecithin
treated cells than to control SEM. Heparinase treatment did not further
increase monocyte binding to lysolecithin-treated SEM. HSPG degrading
activity was found in medium from lysolecithin-treated but not control
cells. SO -labeled products obtained from
labeled matrix treated with lysolecithin-conditioned medium were
similar in size to those generated by heparinase. These data suggest
that lysolecithin-treated endothelial cells secrete a heparanase-like
activity. We hypothesize that decreased vessel wall HSPG, as occurs in
atherogenic conditions, allows increased monocyte retention within the
vessel and is due to the actions of an endothelial heparanase.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Tran-Lundmark, P.-K. Tran, G. Paulsson-Berne, V. Friden, R. Soininen, K. Tryggvason, T. N. Wight, M. G. Kinsella, J. Boren, and U. Hedin
Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation
Circ. Res.,
July 3, 2008;
103(1):
43 - 52.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cohen-Mazor, S. Sela, R. Mazor, N. Ilan, I. Vlodavsky, A. L. Rops, J. van der Vlag, H. I. Cohen, and B. Kristal
Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?
Am J Physiol Heart Circ Physiol,
February 1, 2008;
294(2):
H651 - H658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gong, J. Lu, X. Chen, S. Y. Choong, S. Zhang, Y.-K. Chan, S. Glyn-Jones, G. D. Gamble, A. R. J. Phillips, and G. J. S. Cooper
Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic Rats
Mol. Pharmacol.,
December 1, 2006;
70(6):
2045 - 2051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Vikramadithyan, Y. Kako, G. Chen, Y. Hu, E. Arikawa-Hirasawa, Y. Yamada, and I. J. Goldberg
Atherosclerosis in perlecan heterozygous mice
J. Lipid Res.,
October 1, 2004;
45(10):
1806 - 1812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Vogl-Willis and I. J. Edwards
High Glucose-Induced Alterations in Subendothelial Matrix Perlecan Leads to Increased Monocyte Binding
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2004;
24(5):
858 - 863.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
O. GOLDSHMIDT, E. ZCHARIA, M. COHEN, H. AINGORN, I. COHEN, L. NADAV, B.-Z. KATZ, B. GEIGER, and I. VLODAVSKY
Heparanase mediates cell adhesion independent of its enzymatic activity
FASEB J,
June 1, 2003;
17(9):
1015 - 1025.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gotte, A. M. Joussen, C. Klein, P. Andre, D. D. Wagner, M. T. Hinkes, B. Kirchhof, A. P. Adamis, and M. Bernfield
Role of Syndecan-1 in Leukocyte-Endothelial Interactions in the Ocular Vasculature
Invest. Ophthalmol. Vis. Sci.,
April 1, 2002;
43(4):
1135 - 1141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Paka, I. J. Goldberg, J. C. Obunike, S. Y. Choi, U. Saxena, I. D. Goldberg, and S. Pillarisetti
Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells. AN UNDERLYING MECHANISM FOR THE MODULATION OF SMOOTH MUSCLE CELL GROWTH?
J. Biol. Chem.,
December 17, 1999;
274(51):
36403 - 36408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhang, K. Yoshida, J. Liu, and R. D. Rosenberg
Anticoagulant Heparan Sulfate Precursor Structures in F9 Embryonal Carcinoma Cells
J. Biol. Chem.,
February 26, 1999;
274(9):
5681 - 5691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Paka, Y. Kako, J. C. Obunike, and S. Pillarisetti
Apolipoprotein E Containing High Density Lipoprotein Stimulates Endothelial Production of Heparan Sulfate Rich in Biologically Active Heparin-like Domains. A POTENTIAL MECHANISM FOR THE ANTI-ATHEROGENIC ACTIONS OF VASCULAR APOLIPOPROTEIN E
J. Biol. Chem.,
February 19, 1999;
274(8):
4816 - 4823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. J. Goldberg, W. D. Wagner, L. Pang, L. Paka, L. K. Curtiss, J. A. DeLozier, G. S. Shelness, C. S. H. Young, and S. Pillarisetti
The NH2-terminal Region of Apolipoprotein B Is Sufficient for Lipoprotein Association with Glycosaminoglycans
J. Biol. Chem.,
December 25, 1998;
273(52):
35355 - 35361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. C. Mounkes, W. Zhong, G. Cipres-Palacin, T. D. Heath, and R. J. Debs
Proteoglycans Mediate Cationic Liposome-DNA Complex-based Gene Delivery in Vitro and in Vivo
J. Biol. Chem.,
October 2, 1998;
273(40):
26164 - 26170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Pikas, J.-p. Li, I. Vlodavsky, and U. Lindahl
Substrate Specificity of Heparanases from Human Hepatoma and Platelets
J. Biol. Chem.,
July 24, 1998;
273(30):
18770 - 18777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Romano, E. Romano, S. Bjorkerud, and E. Hurt-Camejo
Ultrastructural Localization of Secretory Type II Phospholipase A2 in Atherosclerotic and Nonatherosclerotic Regions of Human Arteries
Arterioscler. Thromb. Vasc. Biol.,
April 1, 1998;
18(4):
519 - 525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Obunike, S. Paka, S. Pillarisetti, and I. J. Goldberg
Lipoprotein Lipase Can Function as a Monocyte Adhesion Protein
Arterioscler. Thromb. Vasc. Biol.,
July 1, 1997;
17(7):
1414 - 1420.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Pillarisetti, L. Paka, A. Sasaki, T. Vanni-Reyes, B. Yin, N. Parthasarathy, W. D. Wagner, and I. J. Goldberg
Endothelial Cell Heparanase Modulation of Lipoprotein Lipase Activity. EVIDENCE THAT HEPARAN SULFATE OLIGOSACCHARIDE IS AN EXTRACELLULAR CHAPERONE
J. Biol. Chem.,
June 20, 1997;
272(25):
15753 - 15759.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1995 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|